These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37855990)

  • 21. Clinical development of IDH1 inhibitors for cancer therapy.
    Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
    Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.
    Wu MJ; Shi L; Dubrot J; Merritt J; Vijay V; Wei TY; Kessler E; Olander KE; Adil R; Pankaj A; Tummala KS; Weeresekara V; Zhen Y; Wu Q; Luo M; Shen W; García-Beccaria M; Fernández-Vaquero M; Hudson C; Ronseaux S; Sun Y; Saad-Berreta R; Jenkins RW; Wang T; Heikenwälder M; Ferrone CR; Goyal L; Nicolay B; Deshpande V; Kohli RM; Zheng H; Manguso RT; Bardeesy N
    Cancer Discov; 2022 Mar; 12(3):812-835. PubMed ID: 34848557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
    Rabehi T; Quesada S
    Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
    Uson Junior PLS; Borad MJ
    Cancer Manag Res; 2023; 15():1025-1031. PubMed ID: 37746315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of ivosidenib for the treatment of
    Tella SH; Mahipal A
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
    Roboz GJ; DiNardo CD; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Donnellan W; Erba HP; Mannis GN; Pollyea DA; Stein AS; Uy GL; Watts JM; Fathi AT; Kantarjian HM; Tallman MS; Choe S; Dai D; Fan B; Wang H; Zhang V; Yen KE; Kapsalis SM; Hickman D; Liu H; Agresta SV; Wu B; Attar EC; Stone RM
    Blood; 2020 Feb; 135(7):463-471. PubMed ID: 31841594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports.
    Müller C; Franke S; Reisländer T; Keitel V; Venerito M
    Case Rep Oncol; 2024; 17(1):753-762. PubMed ID: 39015644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biology of IDH mutant cholangiocarcinoma.
    Wu MJ; Shi L; Merritt J; Zhu AX; Bardeesy N
    Hepatology; 2022 May; 75(5):1322-1337. PubMed ID: 35226770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
    Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
    Tap WD; Villalobos VM; Cote GM; Burris H; Janku F; Mir O; Beeram M; Wagner AJ; Jiang L; Wu B; Choe S; Yen K; Gliser C; Fan B; Agresta S; Pandya SS; Trent JC
    J Clin Oncol; 2020 May; 38(15):1693-1701. PubMed ID: 32208957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
    Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
    JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
    Choe S; Wang H; DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Watts JM; Pollyea DA; Fathi AT; Tallman MS; Kantarjian HM; Stone RM; Quek L; Konteatis Z; Dang L; Nicolay B; Nejad P; Liu G; Zhang V; Liu H; Goldwasser M; Liu W; Marks K; Bowden C; Biller SA; Attar EC; Wu B
    Blood Adv; 2020 May; 4(9):1894-1905. PubMed ID: 32380538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
    Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors.
    Wang X; Chen Z; Xu J; Tang S; An N; Jiang L; Zhang Y; Zhang S; Zhang Q; Shen Y; Chen S; Lan X; Wang T; Zhai L; Cao S; Guo S; Liu Y; Bi A; Chen Y; Gai X; Duan Y; Zheng Y; Fu Y; Li Y; Yuan L; Tong L; Mo K; Wang M; Lin SH; Tan M; Luo C; Chen Y; Liu J; Zhang Q; Li L; Huang M
    Cell Res; 2022 Jul; 32(7):638-658. PubMed ID: 35459936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.
    Lee CL; O'Kane GM; Mason WP; Zhang WJ; Spiliopoulou P; Hansen AR; Grant RC; Knox JJ; Stockley TL; Zadeh G; Chen EX
    Mol Cancer Ther; 2024 Mar; 23(3):394-399. PubMed ID: 38015561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma.
    Hoy SM
    Target Oncol; 2024 May; 19(3):473-480. PubMed ID: 38724820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
    Lodl E; Ramnaraign B; Sahin I; Wheeler S
    J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.